Evercore ISI Group analyst Daniel Markowitz reiterated an Outperform rating on Minimed Group (MMED) and increased its price target from $20 to $27. This indicates a positive outlook from the analyst, suggesting potential upside for the stock based on their valuation.
Evercore ISI Group analyst Daniel Markowitz maintained an 'Outperform' rating on Minimed Group (MMED) and raised the price target from $20 to $27. This action signals increased confidence from the analyst in MMED's future performance and valuation. For traders, this could be a short-term positive catalyst, potentially leading to increased buying interest as the higher price target suggests significant upside. The long-term implication depends on whether the company's fundamentals align with the analyst's upgraded outlook. The key opportunity for traders is to capitalize on any immediate positive price movement following this news.